Cicaprost is a prostacyclin receptor (IP) agonist and orally active prostacyclin analog with potent systemic and pulmonary vasodilatation and anti-inflammatory activity. In preclinical models, Cicaprost treatment largely prevented the hypercholesterolemia-related impairment of coronary vasodilation and nitric oxide release in Isolated Langendorff-hearts. Cicaprost inhibits proinflammatory chemokines production not only from lipopolysaccharides (LPS) or (tumor necrosis factor-alpha) induced primary human monocyte-derived macrophages but also from LPS-stimulated monocyte-derived dendritic cells. Besides that Cicapost strongly inhibits lymph node and organ metastases of spontaneously metastasizing mammary tumors with a mode of action different from cytostatic or antihormonal drugs. In animal models, Cicaprost prevents metastasis if given continuously from the day of tumor implantation, and is effective in reducing metastasis if treatment is begun following surgical removal of the primary tumor when micrometastases are already present. Clinical trials of Cicaprost in healthy male volunteers demonstrate significant anti-platelet and vasodilatory effects.

Eflumast (RP42068; N-(2-hydroxy-3-acetyl-5-fluorophenyl)-5-carboxamido-1H tetrazole) is an antiallergic agent. It was under development as an orally active antiasthmatic.

Tebuquine (also known as WR 228,258) is an antimalarial agent that is significantly more active than amodiaquine and chloroquine and was the most active compound tested against both strains of Plasmodia. Information about the current use of this drug is not available.

Omocianine was developed as an enhancer of fluorescence optical mammography allowed better detection of more superficially located lesions. It was shown that the lowest doses of omocianine performed best in lesion detection. Diffuse optical tomography using a low-dose fluorescent agent is feasible and safe for breast cancer visualization in patients. This compound participated in phase I clinical trials in Germany and in the Netherlands, however, these studies were discontinued.

Phencarbamide is an anti-spasmodic and anticholinergic drug used during parturition. It has a specific antispasmodic action on the smooth muscle, both directly like papaverine and through the autonomic nervous system (atropine effect). It has also an analgesic effect of its own. Side-effects generally associated with the atropine group of drugs.

Revizinone (R-80122) is a selective phosphodiesterase (PDE) III inhibitor, developed for use in treatment of heart failure and ischaemic heart disorders. Revizinone showed positive inotropic and possibly moderate vasodilating properties in dogs, and it was concluded that revizinone has a clinically favorable cardiovascular profile for acute applications in heart failure. In patients with impaired left ventricular function, revizinone was also found to be a potent positive inotropic agent. The drug was safe, its use not associated with marked vasodilation, and no positive chronotropic effects were reported.

Cortisuzol is a glucocorticoid corticosteroid, discovered by the French company Roussel Uclaf, and claimed to have anti-inflammatory activity in a number of clinical case reports.

LAUROGUADINE is a bactericide, topical antiseptic.

Nortopixantrone (BBR-3438), a member of the 9-aza-anthrapyrazole family, is a DNA topoisomerase inhibitor potentially designed for the treatment of gastric cancer, ovarian cancer. BR 3438 exhibited a unique profile of preclinical activity with a superior efficacy against prostatic carcinoma models compared to reference compounds (doxorubicin and losoxantrone). Nortopixantrone had been in phase II clinical trials with Novuspharma for the treatment of gastric cancer, ovarian cancer and prostate cancer. But this research was discontinued in 2002.

Enilospirone (CERM-3726) is essentially a central stimulant. At low doses (100 mg) it may improve performance and at higher doses it may lead to disturbance of sleep continuity. These effects may not involve DA mechanisms, though changes such as those in REM sleep with chronic ingestion could involve the noradrenergic pathway. The property of the drug, even at low doses, to oppose the deterioration in performance associated with tests of prolonged duration is likely to be due to a mild alerting effect.